Morgan Stanley Call 200 PGR 21.03.../ DE000MG100F6 /
8/5/2024 10:59:07 AM | Chg.-0.49 | Bid4:50:55 PM | Ask4:50:55 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.53EUR | -16.23% | 2.56 Bid Size: 20,000 |
2.60 Ask Size: 20,000 |
Progressive Corporat... | 200.00 USD | 3/21/2025 | Call |
GlobeNewswire
6/25
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire
6/24
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Tri...
GlobeNewswire
6/24
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geo...
GlobeNewswire
6/24
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-4...
GlobeNewswire
6/13
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Progr...
GlobeNewswire
6/12
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo...
GlobeNewswire
6/12
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japa...
GlobeNewswire
6/11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
6/11
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b...
GlobeNewswire
6/11
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclero...
GlobeNewswire
6/10
LifeWallet’s Proprietary Data System is Instrumental in Class Certification Against USAA Property an...